A Study of MT-101 in Subjects With CD5+ Relapsed/Refractory TCL

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

SUSPENDED

Clinical Phase

PHASE1/PHASE2

Total Enrollment

40 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-12-15

Study Completion Date

2025-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a Phase 1/2 study to test the safety, tolerability, and efficacy of the investigational agent MT-101 in patients with T cell Lymphoma. MT-101 is made with myeloid cells collected from the patient's blood. The myeloid cells are modified and later infused back into their veins. The modified myeloid cells recognize the tumor cells and are designed to target and kill them.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

MB-105 in Patients With CD5 Positive T-cell Lymphoma

NCT06534060

Lymphoma, T-Cell

RECRUITING PHASE2

A Study of Imvotamab Monotherapy and in Combination in Subjects With Relapsed/Refractory Non-Hodgkin Lymphoma

NCT04082936

Non-Hodgkin Lymphoma Follicular Lymphoma DLBCL +2 more

TERMINATED PHASE1/PHASE2

Immunostimulatory CpG SD-101 + RT in Recurrent/Progressive Lymphoma After Allogeneic Hematopoietic Cell Transplantation (HCT)

NCT01745354

Lymphoma, Non-Hodgkin Hodgkin Disease

TERMINATED PHASE1

Study Comparing Inotuzumab Ozogamicin In Combination With Rituximab Versus Defined Investigator's Choice In Follicular Non-Hodgkin's Lymphoma (NHL)

NCT00562965

Lymphoma, Follicular

TERMINATED PHASE3

Study of IPH4102 in Patients With Relapsed/Refractory Cutaneous T-cell Lymphomas (CTCL)

NCT02593045

Cutaneous T-Cell Lymphoma

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The research study is divided into two parts. The first part will be to determine the safety and tolerability of the study drug product. During this part of the study, there will be 4 groups of study patients. The first group of patients will receive a low dose of cells, the second group will receive the low dose of cells and lymphodepleting chemotherapy to reduce the number of T cells in the blood, the third group will receive a higher dose of cells, and the fourth group will receive the higher dose of cells and lymphodepleting chemotherapy to reduce the number of T cells in the blood. In the second part of the study, cells with or without chemotherapy will be administered based on results of Part 1 and the safety, tolerability, and efficacy of MT-101 will be assessed. All patient groups will receive 6 doses of drug product over 3 weeks.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Lymphoma, T-Cell, Peripheral Lymphoma, T-Cell, Cutaneous Mycosis Fungoides Adoptive Cellular Immunotherapy Cell Therapy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SEQUENTIAL

Multi-ascending dose escalation

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Cohort 1 and Cohort 3

MT-101

Group Type EXPERIMENTAL

MT-101

Intervention Type BIOLOGICAL

CD5 ATAK cells

Cohort 2 and Cohort 4

MT-101 preceded by conditioning (lymphodepleting) chemotherapy

Group Type EXPERIMENTAL

MT-101 + Conditioning (Lymphodepleting) Chemotherapy

Intervention Type OTHER

IV administration of fludarabine and cyclophosphamide

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

MT-101

CD5 ATAK cells

Intervention Type BIOLOGICAL

MT-101 + Conditioning (Lymphodepleting) Chemotherapy

IV administration of fludarabine and cyclophosphamide

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Adults age \> or equal to18 at the time the Informed Consent is signed
* Refractory or relapsed pathologically confirmed T Cell Lymphoma (TCL): Peripheral T cell Lymphoma not otherwise specified (PTCL-NOS) , Angioimmunoblastic T cell Lymphoma (AITL), ALK-negative anaplastic large cell lymphoma (ALCL), ALK-positive ALCL, or Mycosis Fungoides (MF) stage IIB-IV including large cell transformation
* CD5-expressing tumor by IHC or flow cytometry of tumor biopsy within 3 months of Screening or at Screening
* Eastern Cooperative Oncology Group performance status \< 2
* Adequate organ function as defined in the protocol.

Exclusion Criteria

* B1 and B2 disease (as defined in protocol for subjects with MF)
* Known central nervous system involvement by PTCL
* History of allogeneic transplant
* History of intolerance to leukapheresis, plasmapheresis, or blood donation
* Pregnant or nursing women
* Any acute illness including fever (\> 100.4°F or \> 38°C), except fever related to tumor
* Active systemic bacterial, fungal, or viral infection
* Active chronic infection
* Other primary malignancies, except adequately treated malignancies or complete remission
* Active autoimmune disease that has required systemic therapy in the last 2 years
* History of hemophagocytic lymphohistiocytosis
* History of severe, immediate hypersensitivity reaction attributed to penicillin
* Any other condition that, in the opinion of the Investigator, would make the subject unsuitable for the study or unable to comply with the study requirements.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No